Concert Pharmaceuticals and GlaxoSmithKline (GSK) are to collaborate on the development of deuterium-containing drugs, including CTP-518, a deuterated version of Bristol-Myers Squibb’s HIV protease inhibitor, atazanavir. GSK may be onto a winner here with this unique technology, which has the potential to improve the metabolic properties of drugs, and result in new formulations of existing drugs.